alexgoldberg 454 documentary 11 2 12 MASTER In 2004 Alex Goldberg, then a 20 year old local filmmaker began a documentary on stem cell research at the University of Washington. On June 16 2011, he died before the film was finished. This film highlights the need for this research to continue in order to save thousands of lives. In this unsettling political climate, the film resonates. It was made during the Bush era when stem cell lines were limited, thus stunting the research and in turn a cure for so many diseases.From:Leta GoldbergViews:0 0ratingsTime:15:03More inEducation Continue reading here: alexgoldberg 454 documentary 11 2 12 MASTER - Video … Continue reading →

Romney Obama Elections Gay Marriage, Stem Cell Research Scene TV Aidens Rant. Aiden Rants about the 2012 elections. MooMoo the Emo Cow votes Musical Feature by Aiden Arrows And Jeff Scolley . "America The Beautiful Same Sex Marriage" Spoken Word Song.From:AidenArrowsViews:5 4ratingsTime:07:59More inEntertainment Read the rest here: Romney Obama Elections Gay Marriage, Stem Cell Research Scene TV Aidens Rant. - Video … Continue reading →

Sunday, Nov. 4, 2012 A science ministry working group studying stem cells and regenerative medicine has updated its road map on induced pluripotent stem-cell research, aiming to create human organs including brains, lungs and kidneys via iPS cells within 10 years. The group's updated plan, first compiled in 2009, calls for the distribution of iPS cells for regenerative medicine to start within the next two to three years. The announcement comes after Kyoto University professor Shinya Yamanaka jointly won this year's Nobel Prize in physiology or medicine for his revolutionary work in developing iPS cells. The new road map includes a plan by the government-backed Riken research institute to begin a clinical study in fiscal 2013 on the transplantation of retinas created through iPS cells into patients suffering age-related deterioration in their vision. In addition, a clinical study on heart muscle will start within three to five years, targeting patients who have suffered heart attacks or are experiencing other cardiac diseases. A study on brain nerve cells will also be launched in five to seven years, mainly for patients afflicted with Parkinson's disease. Riken official Shinichi Nishikawa, also a member of the ministry's working group, said researchers from various fields … Continue reading →

The 35 companies and researchers who spoke at last weeks stem cell conference in La Jolla faced a big challenge. They were given just 15 minutes each to pique the interest of potential investors and corporate partners. To get that brief time in the spotlight at the Stem Cell Meeting on the Mesa, they came from across the country; two came from Europe. Nearly all of them shared the goal of using stem cells and the bodys own regenerative ability to treat diseases and injuries. But their approaches to regenerative medicine vary greatly. Many are tackling diseases such as diabetes, cardiovascular disease and hair regeneration. Some aim to provide new and useful stem cell types. Others provide equipment to expand regenerative medicines tool chest. Here are five of the presentations: Aderans Research Institute: Your own hair, back again. Thats the allure of Atlanta-based Aderans Ji Gami hair growth process. Patients donate hair-containing skin from their neck, and Aderans cultivates the hair follicle-forming cells. These cells are then injected back into the patient. The cells stimulate new hair production in dormant hair follicles, working on male or female pattern baldness, said Aderans Chief Executive Ken Washenik. They have been tested in … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/pnsgjh/commercializing) has announced the addition of Woodhead Publishing Ltd's new book "Commercializing the stem cell sciences" to their offering. Commercializing the Stem Cell Sciences offers a comparative analysis of the commercial methods adopted in the global stem cell industries, and seeks to establish whether there is an optimum commercial model, and to examine what emerging companies can learn from their predecessors. Following an introduction to stem cell sciences and the problems involved in their commercialization, the book begins with a discussion of stem cell treatments from a global perspective, and the role of innovation in the commercialization of biotechnology in general. In the second half of the book, chapters focus on the different strategies that can be employed and their relative risks and values, before a conclusion that looks at potential new developments in the field. Key Topics Covered: - Introduction: Stem cell science, biotechnology and the problem of commercialization - Stem cell treatments in a global marketplace - The role of innovation systems in the commercialization of biotechnology - Low-risk, low value strategies: Adult stem cells - High-risk, high-value: embryonic stem cells - Low-risk, low-value: iPS cells See the original post: Research and Markets: … Continue reading →